@JDRFResearch

JDRF funds research that transforms the lives of people with type 1 diabetes (T1D). We want a cure, and we won’t stop until we find one.

 New York, NY
Joined March 2018
  • Tweets609
  • Following63
  • Followers2.4K
113Media
BREAKING NEWS! A CDC advisory committee voted 14-0 recommending the use of the Pfizer/BioNTech COVID-19 vaccine in children ages 5-11. The CDC Director will soon make a recommendation on behalf of the CDC. Stay tuned for more details!
1
3
1
14
Vertex VX-880 shows promising data from its Phase 1/2 Clinical Trial, including a 91% reduction in daily insulin requirement after 90 days. Learn more: jdrf.org/blog/2021/10/18/ver…
4
16
2
57
JDRF mourns the loss of T1D researcher Stacey Anderson, M.D. Read about her many contributions to the T1D here: jdrf.org/blog/2021/10/05/jdr…

Breakthrough T1D Mourns the Loss of Stacey Anderson, M.D. - Breakthrough T1D

Stacey Anderson, M.D., was a tireless champion for the type 1 diabetes (T1D) community, a brilliant researcher, and a dedicated physician.

breakthrought1d.org
2
3
Last week, @JDRF and @NIDDKgov brought together the top minds in immunology, material science, bioengineering, transplants and more to discuss keeping transplanted beta cells healthy through immune tolerance and localized immune modulation. Learn more: jdrf.org/blog/2021/08/09/jdr…

Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering - Breakthrough...

Dive into the intersection of immunology and bioengineering at the Breakthrough T1D-NIH workshop. Discover the latest research and collaborative efforts here.

breakthrought1d.org
3
1
10
Good news for the T1D community: @US_FDA has approved Semglee® as the first interchangeable biosimilar insulin product. Learn more at the blog: jdrf.org/blog/2021/07/29/fda…

FDA Approves Semglee® as the First Interchangeable Biosimilar Insulin Product

Discover how the FDA’s approval of Semglee as the first interchangeable biosimilar insulin product marks a major breakthrough for people with type 1 diabetes.

breakthrought1d.org
12
19
Dr. Nikki Farnsworth discusses her research around beta cell death and how she's working to identify potential targets to help prevent beta cell death. #JDRFxADA #ADA2021
1
4
19
Check out our recap of Day 1 of the @AmDiabetesAssn's Scientific Sessions at the link below! #JDRFxADA #ADA2021 ow.ly/rejm50Fj5OJ

Video: ADA’s Scientific Sessions: Day 1: Breakthrough T1D Researchers Report

Here are Drs. Candace Reno and Luiza Caramori share their key takeaways from day 1, with their commentary in the video and below.

breakthrought1d.org
1
3
Join us at 7pm ET for a Facebook Premiere event featuring key takeaways from Day 1 of The @AmDiabetesAssn's Scientific Sessions. Tune in at facebook.com/myJDRF #JDRFxADA #ADA2021
1
3
Elad Sintov discusses his work focuses around building genetic modifications in stem cells as a replacement therapy for type 1 diabetes (T1D). #JDRFxADA #ADA2021
1
1
6
Adriana Migliorini discusses her work, which is focused around understanding immune cells and endocrine cells during human pancreatic development #JDRFxADA #ADA2021
13
1
33
JDRF's Vice President of Research, Dr. Sanjoy Dutta shares what you can expect to learn from The @AmDiabetesAssn's 81st annual Scientific Sessions and how we'll be keeping you updated. #JDRFxADA #ADA2021
6
15
At 1pm ET JDRF's Vice President of Research, Dr. Sanjoy Dutta will be giving a preview of what you can expect to learn from the @AmDiabetesAssn 81st Scientific Sessions, and how we'll be keeping you updated! #JDRFxADA #ADA2021
1
5
We are proud to announce that Kevan Herold, M.D., C.N.H., Long Professor of Immunobiology and professor of medicine at Yale University, has been named chair of Type 1 Diabetes TrialNet. Congratulations, Dr. Herold! trialnet.org/events-news/blo… @NIDDKgov
7
1
38
JDRF Vice President of Research, Sanjoy Dutta, Ph.D., congratulates Kevan Herald, M.D. on his appointment as the new TrialNet Chair. Read more: jdrf.org/press-releases/stat…
1
7
JDRF applauds the U.S. Food and Drug Administration’s (FDA) Advisory Committee positive recommendation in support of approval of teplizumab for those at risk for developing clinical T1D. Learn more here: ow.ly/kt0f50EXfnB
13
3
30
Life with T1D is tough. That's why JDRF is observing Mental Health Awareness Month and supporting psychosocial health issues in people with T1D through the JDRF Behavioral Health and Psychology Program. Learn more at the blog: jdrf.org/blog/2021/05/24/jdr…
1
2
May 20th is Clinical Trials Day! Today, we want to raise awareness about them and the pivotal role they play in bringing new therapies into the hands of the T1D community. Learn more, including how to find a clinical trial, at the blog. jdrf.org/blog/2021/05/20/adv…

Breakthrough T1D Advancing Cures with Type 1 Diabetes Clinical Trials

Discover the latest advancements in clinical trials for type 1 diabetes and the progress towards finding cures.

breakthrought1d.org
1
7
1
18
We also want to thank and celebrate everyone who has been in a clinical trial. You are heroes!
1
5
BREAKING: The Bigfoot Unity™ Diabetes Management by Bigfoot Biomedical has received U.S. Food and Drug Administration clearance for individuals 12 and older. For the first time, people who use multiple daily injections (MDI) to manage their diabetes will be able to (1/2)
2
10
2
42
The 13th @DiabetesnPOD annual meeting took place last week, featuring some of the world's brightest T1D researchers. We have a recap over at the blog. jdrf.org/blog/2021/03/03/ben…

Breakthrough T1D-nPOD Annual Conference

The 13th nPOD Annual Meeting was held February 22-24, 2021, and featured some of the most world-renowned diabetes investigators.

breakthrought1d.org
3
11
Load more